Cocaine esterase - Tonix Pharmaceuticals Holding Corp
Alternative Names: Cocaine esterase; RBP 8000; T172R/G173G cocaine esterase; T172R/G173Q double-mutant cocaine esterase; TNX 1300Latest Information Update: 15 Jul 2024
At a glance
- Originator Columbia University; University of Kentucky; University of Michigan
- Developer Indivior
- Class Antidotes; Carboxylic ester hydrolases; Drug withdrawal therapies
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cocaine-related disorders
Most Recent Events
- 27 Jun 2024 Tonix Pharmaceuticals initiates a phase II CATALYST trial for Cocaine-related disorders in USA (IV, infusion) (NCT06045793)
- 01 Apr 2024 Tonix Pharmaceuticals plans a phase II trial for Cocaine-related disorders in the US in the second quarter of 2024
- 13 Mar 2023 Tonix Pharmaceuticals has patent protection for Cocaine esterase in Canada, New Zealand, Europe – (Germany, Spain, France, United Kingdom, and Italy), South Africa, Mexico and Israel